Welcome to the Global PAH programme

The Global Potentially Avoidable Hospitalisations programme, initiated and funded by AstraZeneca, brings together research and expert perspectives to explore how health systems can help reduce potentially avoidable hospitalisations.

This non-promotional resource is intended for healthcare professionals, decision-makers, and advocates involved in health policy development. It includes microsimulation modelling conducted by HealthLumen and a policy report developed by The Health Policy Partnership (HPP), informed by a Steering Committee of 12 global experts in health, policy, and advocacy.

The programme offers evidence and recommendations to support holistic health-system reform and optimise the use of guideline-directed medical therapy (GDMT).

Chronic conditions are contributing to a growing  number of potentially avoidable hospital admissions

31% rise

in the number of chronic condition cases by 2050¹Organisation for Economic Co-operation and Development, 2026.
Over 60%

of older adults have more than one chronic condition² Organisation for Economic Co-operation and Development, 2025.
4% reduction in GDP

by 2050 due to chronic conditions¹ Organisation for Economic Co-operation and Development, 2026.

Complete uptake of guideline-directed medical therapy could lead to

32.3%

of primary-cause hospitalisations potentially avoided each year (5 conditions, 6 countries)
114.8 million

bed days avoided (5 conditions, 6 countries over 10 years)
US$36.2 billion

of productivity protected (5 conditions, 6 countries over 10 years)

Featured policy report

Reducing avoidable hospitalisations: the case for optimised treatment

Discover key policy recommendations informed by novel modelling of how increased adoption of GDMT could help reduce avoidable hospitalisations across five major chronic conditions.

Download policy report

Our Steering Committee

Guided by global expertise

The Global PAH Study is guided by an independent, multidisciplinary Steering Committee of 12 experts in clinical care, health policy, academia and patient advocacy. Steering Committee members reviewed the study’s modelling approach and helped shape the recommendations presented in the policy report.